Identification of risk groups for advanced liver fibrosis in the general population using the Fibrosis‐3 index
Kazuya Kariyama,
Miwa Kawanaka,
Kazuhiro Nouso,
Akiko Wakuta,
Shohei Shiota,
Akemi Kurisu,
Aya Sugiyama,
Tomoyuki Akita,
Takashi Kumada,
Junko Tanaka,
the Real‐Life Practice Experts for HCC (RELPEC) Study Group
Affiliations
Kazuya Kariyama
Department of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan
Miwa Kawanaka
Department of General Internal Medicine 2 General Medical Center, Kawasaki Medical School Okayama City Okayama Japan
Kazuhiro Nouso
Department of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan
Akiko Wakuta
Department of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan
Shohei Shiota
Department of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan
Akemi Kurisu
Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan
Aya Sugiyama
Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan
Tomoyuki Akita
Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan
Takashi Kumada
Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki City Gifu Japan
Junko Tanaka
Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan
the Real‐Life Practice Experts for HCC (RELPEC) Study Group
Abstract Background and Aim We conducted a study using the Fibrosis‐3 (FIB‐3) index, which is the established age‐independent index of fibrosis in nonviral liver disease and addresses the limitations of the FIB‐4 index in older age group, to assess the liver fibrosis risk among diverse demographic groups in the general population. Methods We analyzed 31 327 individuals who underwent health examinations between 2013 and 2020 and investigated the distribution of the FIB‐3 index by age group. In addition, we examined the age distribution of the FIB‐3 index stratified by background factors, such as sex, body mass index (BMI), alcohol consumption habits, and the presence or absence of fatty liver. Results In terms of age‐specific distribution, the FIB‐3 index remained below 1.5 in >90% of cases until the age of 50 years but exceeded 1.5 beyond the age of 50 years, in approximately 30% among those aged 70 years. Notably, the FIB‐3 index above 31 years old was significantly higher in men than in women. Among the different BMI categories, individuals with BMI < 18.5 exhibited the highest prevalence of fibrosis. Habitual drinkers had a higher proportion with FIB‐3. index ≥1.5, and some had FIB‐3 index ≥2.5, raising the suspicion of advanced hepatic fibrosis. No distinct association was identified between the FIB‐3 index and the presence of fatty liver. Conclusions The FIB‐3 index was useful for identifying cases of advancing hepatic fibrosis in a health checkup population. Liver fibrosis progresses with age in the general population, especially among men, those with low BMI, and habitual drinkers.